학술논문

Advances in Tumour-Infiltrating Lymphocytes for Triple-Negative Breast Cancer Management
Document Type
Academic Journal
Source
Breast Cancer: Targets and Therapy. November 30, 2023, Vol. 15, p773, 11 p.
Subject
Company business management
United States. Food and Drug Administration -- Management
University of Maribor -- Management
Medical research -- Health aspects
Medicine, Experimental -- Health aspects
Progesterone -- Health aspects
Immunotherapy -- Health aspects
B cells -- Health aspects
Estrogen -- Health aspects
Breast cancer -- Prognosis -- Development and progression
Language
English
ISSN
1179-1314
Abstract
Triple negative breast cancer (TNBC) is a subtype of breast cancer which does not express or expresses a minimum amount of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor 2 (HER2) protein. TNBCs include a heterogenic group of cancers that are aggressive, grow rapidly and are associated with poor prognosis and overall survival, mainly attributed to a lack of effective therapeutic targets. For a long time, a major issue with predicting the outcome and prognosis of TNBCs was the lack of an accurate biomarker, a molecule that helps us objectively assess a patient's health status. In recent times, defining the presence of tumor-infiltrating lymphocytes (TIL) is becoming an indispensable method of determining a patient's prognosis. TILs are found in tumor tissue and the surrounding stroma and carry a prognostic value. Furthermore, they are known to improve the effect of systemic therapy. With the rise of immunotherapy, the role of TIL in this newer therapeutic option is a topic of increased importance. The goal behind this research article is a comprehensive review of the current literature on the importance of tumor-infiltrating lymphocytes in the prognosis of TNBC. Keywords: tumor-infiltrating lymphocytes, immunotherapy, prognosis, dysfunction/exhaustion, microenvironment, immunometabolism
Introduction Triple-negative breast cancer (TNBC) is a subtype of breast cancer that does not express or expresses a minimum amount of estrogen receptors (ER), progesterone receptors (PR) and human epidermal [...]